Taiba expects to launch Kalbitor in 2012. The profits on Kalbitor sales within the licensed territory will be shared by Dyax and taiba.
Dyax president and chief executive officer Gustav Christensen said taiba brings Kalbitor to HAE patients within a part of the world with great unmet medical need for an effective HAE therapy.
The plasma kallikrein inhibitor indicated for the treatment of acute attacks of HAE in patients 16 years of age and older was discovered and developed by Dyax.
Taiba managing director Saif Al Hasani said Kalbitor will offer HAE patients an important new treatment option.
"Using our extensive experience in the orphan drug space we can rapidly and effectively engage relevant stakeholders to increase awareness of both HAE and Kalbitor," Al Hasani added.